Board of Directors


Jon Moulton

Non-Executive Chairman

Jon has been an institutional and personal investor in numerous biotech and pharma companies over the past 30 years. He established Schroder Life Sciences, which was the initial venture capital investor in Shire.

He is now Chairman of several companies including finnCap, the leading AIM broker, a trustee of the UK Stem Cell Foundation and is also the primary funder of a substantial clinical trials charity.

Dr Peter Jackson

Executive Director

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.

Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director then VP of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

During 2015-16, Dr Jackson was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.

Dr Tony Flinn

Non-Executive Director

An entrepreneur and general business manager with competence in research, development, applied technology, sales, marketing, new business development, finance, business planning, business funding and general management.

Originally a scientist with a degree and PhD in chemistry, Tony started in research then moved to development and technical management roles. In 2000 he founded Onyx Scientific Ltd and as CEO with major business development responsibilities grew the business successfully. The company won the NE Small Business of the Year award and was cited as a top 20 fastest growing technology company in the UK. In 2007 Tony managed an MBO and in 2011, a trade sale. Tony has subsequently been involved in several successful life science and consumer businesses and currently operates as a business coach, mentor and advisor, motivational speaker, non-exec director and management consultant.

Dr Chris Doherty

Non-Executive Director

A graduate pharmacist later completing a PhD, a Post-Doctoral Fellowship in pharmaceutical technology and then an MBA, Chris has worked at three large pharma companies over 26 years: Glaxo in Canada/UK in development and production roles; Roche as Head of Pharmacy R&D for the UK; and then AstraZeneca in 1997 to lead an international pharmaceutical sciences group. This was followed by broader experience running R&D/commercial/clinical teams for late phase development projects in oncology as well as a site leadership role at Alderley Park.

Chris is currently Managing Director, Alderley Park for the site’s owners Bruntwood, with responsibility for the science park, C-Level company engagement and investment fund aspects. There are 58 established companies at the site and circa 94 companies have been incorporated there, many working through the pre-start incubation programme. All are in the Biotech sector or associated with it including a number in the AMR field.

Pauline Stasiak PhD

Non-Executive Director

Pauline Stasiak is Investment Principal in LifeArc’s Seed Fund. LifeArc is a medical charity with a mission to turn great science into greater patient impact. The Seed Fund invests in early stage therapeutics companies in the UK focussing on addressing diseases with high unmet medical need.

Pauline graduated from UCL with a degree in microbiology followed by a PhD in cell and molecular biology at the Imperial Cancer Research Fund. She undertook post-doctoral research at Stanford University investigating cytomegalovirus gene regulation and at British BioTechnology developing Virus Like Particles of SIV as a model for HIV therapy. She has 26 years’ experience in technology transfer at both the Ludwig Institute for Cancer Research and at LifeArc identifying and facilitating the translation of early stage research into patient benefit. This included a secondment from LifeArc for 15 months working as an Investment Manager for the UCL Technology Fund with UCL Business and Albion Capital.

She has a MSc in the management of intellectual property from Queen Mary College London and for several years was on the Patent Board of Telethon, Italy, advising Telethon on intellectual property management and commercialisation strategy. She is also a judge for the Young Entrepreneurs Scheme (YES) run by the Biotechnology and Biological Sciences Research Council (BBSRC) and the University of Nottingham helping to encourage an entrepreneurial culture in the life science post-graduate and post-doctoral community.

Management


Dr Peter Jackson

Executive Director

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.

Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director then VP of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

During 2015-16, Dr Jackson was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.

Dr Derek Lindsay

Chief Operating Officer

Derek was a co-founder of Redx Pharma and its Chief Operating Officer from 2012-17. His former roles include being a Director of Innovation of pharmaceutical industry consortium Britest Ltd from 2006 to 2012, and R&D Director of Avecia Pharmaceutical Products in a management career of more than 30 years. Derek has worked in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985.

Chief Financial Officer

Dawn Watson

Experienced Financial Director of both high potential start-ups and established businesses across a broad range of industries. Having trained with Ernst & Young and after gaining many years in industry established her own company in 2010, FinStra Ltd, to provide strategic and financial support either as a part time or ad hoc Finance Director together with undertaking specific projects to help companies achieve their full potential.

Dr Ian Cooper

Head of Chemistry

Ian is an experienced medicinal chemist with over 14 years drug discovery experience from hit identification through to the delivery of clinical candidates, across a range of therapeutic areas, including anti-infectives, neurology, pain and inflammation. He previously held senior positions at Redx Anti-infectives, GlaxoSmithKline and Insight Chemical Solutions.  Ian currently leads an experienced and skilful medicinal chemistry department progressing multiple programs focussed on combating the threat of antibiotic resistance.

Dr Victoria Savage

Head of Biology

Dr Victoria Savage is an experienced microbiologist with over 10 years’ experience in antibiotic research and development. She gained a First-class BSc Hons in Microbiology and Immunology at the University of Leeds and consequently pursued a PhD, and postdoctoral research fellowships, investigating antibiotic resistance in bacteria. More recently, she managed the bacteriology team at Redx Anti-Infectives as Principal Microbiologist. She has worked on a diverse array of antibiotic development projects from hit-to-lead through to candidate selection, and now manages the biology team at the AMR Centre.

Carl Curran

Marketing & Communications Executive

PR, marketing & communications professional, with an extensive background in stakeholder liaison, public relations, and project management. Solid experience gained within a governing UK political party, and in the private sector. Carl managed a successful national campaign during the 2015 General Election.

Scientific & Technical Advisory Board


Prof. Ian Greer

S&TAB Chairman

Chairman of the NHSA, Vice President of the University of Manchester and Dean of its faculty of Medical and Human Sciences

Prof. William Hope

University of Liverpool (Clinician-scientist; PK-PD modelling; pre-clinical development; anti-fungal drug discovery

Prof. Jeff Errington

Newcastle University (Microbiology; small-molecule antibacterial discovery research; natural product discovery; bacterial cell biology; founder of Prolysis Ltd and Demuris Ltd)

Prof. David Livermore

University of East Anglia (Medical microbiology; antibiotic resistance mechanisms, particularly beta-lactamases; epidemiology)

Dr Nell Moore

Vice President, Clinical Development AstraZeneca Antibiotics

Dr David Cook

Chief Scientific Officer, Blueberry Therapeutics